mitoxantrone + vincristine + dexamethasone + pegaspargase

This is a **four-drug chemotherapy combination** consisting of mitoxantrone, vincristine, dexamethasone, and pegaspargase. - **Mitoxantrone** is an anthracenedione antineoplastic agent that intercalates into DNA, inhibits topoisomerase II, and disrupts DNA synthesis and repair, leading to cytotoxicity in rapidly dividing cells. - **Vincristine** is a vinca alkaloid that inhibits microtubule formation in mitotic spindle, causing arrest of dividing cells in metaphase. - **Dexamethasone** is a synthetic glucocorticoid with anti-inflammatory and lympholytic properties, used to induce apoptosis in certain malignancies. - **Pegaspargase** is an enzyme (a pegylated form of L-asparaginase) that hydrolyzes asparagine to aspartic acid and ammonia, depriving tumor cells (particularly lymphoblasts) of the essential amino acid asparagine. This combination may be used for the treatment of **acute lymphoblastic leukemia (ALL)**, particularly in relapsed or refractory settings. The specific combination has been studied as an alternative to traditional anthracycline-based regimens, such as for patients with a first relapse of ALL[4].